Objectives
The primary objective was to determine the 3-year programme sensitivity of annual FITs compared with colonoscopy surveillance at 3 years for detecting CRC or AAs in intermediate-risk patients, following polypectomy after a positive gFOBT.
Secondary objectives were to:
l estimate the diagnostic accuracy of FITs at first, second and third tests and over two or three tests at various thresholds l examine the acceptability of FITs, compared with colonoscopy, as a surveillance strategy for people at increased risk of CRC l calculate the incremental costs and cost-effectiveness of FITs versus colonoscopy surveillance.
Methods
Eligible individuals were those aged 60-72 years who were categorised as being at intermediate risk following polypectomy at colonoscopy conducted < 1 year previously following a positive gFOBT in the BCSP, and were scheduled for surveillance colonoscopy 3 years after initial colonoscopy in line with UK guidelines [Atkin WS, Saunders BP, British Society for Gastroenterology. Surveillance guidelines after removal of colorectal adenomatous polyps. Gut 2002;51(Suppl. 5):V6-9].
Consecutive individuals meeting the eligibility criteria were sent a FIT and invited to participate in the study by the BCSP Southern Hub between January 2012 and December 2013. The FIT kit contained instructions, an information sheet, a FIT sampling device (OC-AUTO Sampling Bottle 3, Eiken Chemical Co. Ltd, Tokyo, Japan), a plastic zip-lock bag and a pre-paid envelope in which to return the completed kit and consent form.
Eligible individuals who returned a completed consent form and analysable FIT were included in the study. Laboratory analysis of FITs was conducted using the OC-Sensor DIANA (Eiken Chemical Co. Ltd, supplied by MAST Diagnostics Division, UK). The faecal haemoglobin threshold was initially 20 µg of haemoglobin/g faeces(hereafter referred to as µg/g); however, as positivity was higher than expected in the pilot study, the threshold was raised to 40 µg/g. The study involved three rounds of FIT, conducted at 1, 2 and 3 years post baseline colonoscopy. Only participants returning a round 1 FIT were invited to subsequent rounds. Participants testing positive at round 1 or 2 were offered early colonoscopy and were not invited to further rounds. Participants testing negative at round 1 were invited to round 2. A round 3 FIT was sent to participants testing negative at round 2, and to participants who did not return an analysable round 2 FIT. Participants invited to round 3 were scheduled for colonoscopy at 3 years post baseline colonoscopy, in line with UK guidelines (Atkin and Saunders 2002).
We calculated uptake and positivity of FIT at each round. We analysed sensitivity, specificity, PPVs and negative predictive values (NPVs) of FIT for CRC, AAs and advanced colorectal neoplasia (ACN) (CRC and/or AAs) at various thresholds (40 µg/g, 30 µg/g, 20 µg/g and 10 µg/g) and over multiple rounds. We assumed that any ACN detected was present and would remain present and unchanged in the absence of colonic examination at years 1, 2 and 3, and that the same neoplasia would be detected regardless of the year at which examination occurred.
For analysis of multiple rounds, we performed a cumulative test analysis and a programme analysis. In the programme analysis, we included all participants and categorised as positive anyone testing positive in the first or second round (two-tests analysis), or in the first, second or third round (three-tests analysis). For the cumulative test analysis, we included only participants who were compliant with testing (i.e. they completed the SCIENTIFIC SUMMARY: POST-POLYPECTOMY SURVEILLANCE: FIT VS. COLONOSCOPY NIHR Journals Library www.journalslibrary.nihr.ac.uk iv specified number of rounds, two for two-test analysis or three for three-test analysis, or tested positive at a previous round).
Health psychology assessment
There were two components to the health psychology assessment: (1) a qualitative discussion group study assessing attitudes towards FIT as an alternative to colonoscopy surveillance in adults with varied CRC risk and experience of colonoscopy, and (2) an evaluation of the psychological impact and acceptability of annual FIT and preferences for future surveillance using questionnaires and interviews.
For the discussion groups, 198 adults aged 60-74 years, with different levels of CRC risk and varying amounts of experience with gFOBT and colonoscopy, were identified by the BCSP London Hub and St Mark's Hospital Endoscopy Unit.
Five discussion groups were held in 2011 using a comprehensive stepwise discussion guide. After each section, participants were asked to 'consider the information you have just seen about FIT replacing a routine colonoscopy. How would you feel about the offer of a FIT every year instead of a 3-yearly colonoscopy?'. Participants used an electronic device to select an option on a six-point scale from 'very positive' to 'very negative'.
The views of FIT for Follow-Up study participants were gathered through questionnaires at baseline and at each round. In addition, a subsample of participants underwent end-of-study interviews. In the baseline questionnaire, participants were asked to rate their experience of baseline colonoscopy, level of CRC-related worry and current emotional state using the Spielberger State-Trait Anxiety Inventory (STAI). The questionnaires queried participants' experience of completing FIT. Questionnaires at each round queried emotional well-being and CRC-related worry.
Economic evaluation
We assessed incremental costs and cost-effectiveness of annual FIT with colonoscopy only for a positive result, as an alternative to colonoscopy at 3 years, for the surveillance of intermediate-risk patients.
The cost of each surveillance regimen was estimated. Cost-effectiveness is presented as the incremental cost-effectiveness (i.e. saving) per AA that was not detected by FIT versus colonoscopy surveillance, and the incremental cost-effectiveness per CRC that was not detected by FIT versus colonoscopy surveillance.
Costs were restricted to those from surveillance and did not include treatment costs, other than the cost of adenoma removal as a result of FIT positivity. Unit costs were obtained from the NHS Reference Costs 2014 to 2015 (Department of Health and Social Care. NHS Reference Costs 2014 to 2015. London: Department of Health and Social Care; 2015) . Sensitivity analyses explored the effect of different FIT thresholds and diagnostic procedure costs on cost-effectiveness. We estimated the budget impact if annual FIT surveillance was implemented nationally instead of 3-yearly colonoscopy surveillance.
Results
Of the 9851 individuals identified as potentially eligible, 296 were excluded and 1547 were not invited because the target sample size had been reached. The remaining 8008 were invited to participate and 5948 (74.3%) consented and completed a FIT. Two individuals subsequently withdrew, leaving a cohort of 5946 individuals in round 1. Uptake of FIT in rounds 2 and 3 was 97.2% (5350/5503) and 96.9% (5058/5220), respectively.
With a threshold of 40 µg/g, FIT positivity was 5.8% (347/5946) in round 1, decreasing to 4.1% (206/5058) in round 3. Positivity in each round was greater in men than in women (round 1: 6.6% vs. 4.3%, respectively) and in older participants (> 65 years) than in younger participants (≤ 65 years) (round 1: 6.5% vs. 5.1%, respectively). Over all three rounds, cumulative attendance for colonic examination following a positive FIT was 93.6% (744/795). Among participants with only negative FITs, attendance for end-of-study colonic examination was 88.4% (4455/5039).
Among the 5199 participants who had a colonic examination, either following a positive FIT (n = 744) or at the end of the study (n = 4455), CRC was identified in 0.5% (26/5199) and AAs in 8.5% (443/5199), with both being identified in six participants. In total, 8.9% (463/5199) of participants were diagnosed with ACN (CRC and/or AA). Over all three rounds, 69.2% (18/26) of participants with CRC, 34.3% (152/443) with AAs and 35.6% (165/463) with ACN tested FIT positive with the 40 µg/g threshold.
FIT positivity increased at lower thresholds; for instance, 5.8% (344/5946) tested positive with the first FIT at 40 µg/g, whereas 14.2% (844/5946) tested positive at 10 µg/g. Sensitivity increased, whereas specificity decreased, with lower thresholds. Sensitivity and specificity of the first FIT for CRC were 30.8% (8/26) and 93.9% (4855/5173), respectively, at 40 µg/g, and 61.5% (16/26) and 86.0% (4447/5173), respectively, at 10 µg/g. Sensitivity for AAs was lower, and specificity higher, than for CRC. For example, sensitivity and specificity of the first FIT for AAs were 17.6% (78/443) and 94.8% (4508/4756), respectively, at 40 µg/g, and 33.2% (147/443) and 87.5% (4161/4756), respectively, at 10 µg/g. Taking into account multiple FIT rounds, sensitivity increased but specificity decreased. In programme analysis, sensitivity and specificity for CRC at 40 µg/g were, respectively, 61.5% (16/26) and 89.5% (4630/5173) over two rounds, and 69.2% (18/26) and 86.0% (4450/5173) over three. Similarly, in cumulative test analysis, sensitivity and specificity for CRC at 40 µg/g were, respectively, 66.7% (16/24) and 89.4% (4596/5139) for two tests, and 81.8% (18/22) and 85.4% (4243/4966) for three tests.
Health psychology assessment
In total, 28 people with different levels of CRC risk took part in five qualitative discussion groups. Previous experience of surveillance and level of CRC risk were associated with attitudes towards FIT. All groups thought that FIT would be easier and safer as a surveillance method than colonoscopy. However, individuals with prior experience of surveillance were concerned about the ability of FIT to detect lesions, and particularly that single-sample FIT might not detect polyps that bleed intermittently.
FIT for Follow-Up study participants were invited to complete questionnaires during the study, and a subset of FIT-positive participants was invited to be interviewed at the end of each round. A baseline questionnaire was completed by 98.9% (5879/5946) of participants. Questionnaires were completed by 84.4% (5020/5946) of participants at the end of round 1, 83.9% (4491/5350) at the end of round 2 and 83.5% (3881/4646) at the end of round 3.
In the baseline questionnaire, the vast majority of participants (95.8%, 5370/5604) were satisfied with their baseline colonoscopy. Most participants reported that catching the bowel motion, removing the stick, collecting the sample with the stick, reinserting the stick into the sampling bottle and closing the sampling bottle (94.9%, 99.0%, 97.1%, 95.4% and 99.3%, respectively) was easy.
Of round 1 questionnaire responders, 26.8% (1307/4877) reported that doing FIT made them anxious and 29.2% (1416/4856) reported that they were concerned about the ability of FIT to detect new polyps. Examining STAI scores, anxiety was higher at baseline than at rounds 1, 2 and 3. Participants reported high levels of reassurance, feeling more hopeful and less anxious as a result of participating in the study.
Participants' preferred surveillance strategy was 3-yearly colonoscopy plus annual FIT (57.9%, 2478/4279), followed by annual FIT with colonoscopy only for a positive result (31.5%, 1347/4279). The least preferred strategies included 3-yearly colonoscopy and no FIT (8.9%, 379/4279), and no surveillance (1.8%, 75/4279).
In end-of-study interviews, participants generally reported being very satisfied with taking part in the study. They reported that a FIT was easier to complete than a gFOBT and they appreciated the reassurance that annual FIT provided.
Economic evaluation
Among the 5946 study participants, we estimated the cost of colonoscopy surveillance at 3 years to be £2,633,382, whereas the cost of annual FIT surveillance using a threshold of 40 µg/g was £485,236. However, FITs were also less effective at detecting ACN. Using a threshold of 40 µg/g, three rounds of FITs missed 291 AAs and eight CRCs. The incremental cost-effectiveness (i.e. saving) from FITs was £7382 per AA not detected and £268,518 per CRC not detected.
The estimated cost of FITs depended on the threshold, ranging from £485,236 using 40 µg/g to £956,602 using 10 µg/g. The incremental cost-effectiveness improved with lower thresholds because of fewer missed lesions. At the lowest studied threshold, the incremental cost-effectiveness was £8872 per AA not detected and £419,195 per CRC not detected. The budget impact of replacing colonoscopy surveillance with FIT surveillance ranged from -£4.6M at a threshold of 40 µg/g to -£3.6M at a threshold of 10 µg/g.
Conclusions
This study demonstrated the potential utility of FITs in the surveillance of intermediate-risk patients post polypectomy. Annual low-threshold FIT with colonoscopy in positive cases achieved high cumulative sensitivity for CRC and would be cost saving compared with 3-yearly colonoscopy. However, at higher thresholds, this strategy could miss 15-30% of CRCs and 40-70% of AAs. Participants' preferred surveillance strategy was annual FIT plus 3-yearly colonoscopy. Further research is needed to define a clear role for FITs in surveillance, including evaluation of the implications of missed ACN, considering effects on quality-adjusted life-years.
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